Quest Diagnostics Incorporated $DGX Shares Sold by Te Ahumairangi Investment Management Ltd

Te Ahumairangi Investment Management Ltd decreased its stake in Quest Diagnostics Incorporated (NYSE:DGX) by 10.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 34,536 shares of the medical research company’s stock after selling 3,922 shares during the period. Quest Diagnostics accounts for 1.1% of Te Ahumairangi Investment Management Ltd’s investment portfolio, making the stock its 27th largest holding. Te Ahumairangi Investment Management Ltd’s holdings in Quest Diagnostics were worth $5,993,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of DGX. JFS Wealth Advisors LLC boosted its holdings in shares of Quest Diagnostics by 114.3% in the 4th quarter. JFS Wealth Advisors LLC now owns 150 shares of the medical research company’s stock valued at $26,000 after buying an additional 80 shares in the last quarter. Harbor Investment Advisory LLC increased its position in Quest Diagnostics by 113.7% during the fourth quarter. Harbor Investment Advisory LLC now owns 156 shares of the medical research company’s stock worth $27,000 after buying an additional 83 shares during the period. Sittner & Nelson LLC acquired a new position in Quest Diagnostics during the fourth quarter worth approximately $29,000. McIlrath & Eck LLC acquired a new position in Quest Diagnostics during the fourth quarter worth approximately $32,000. Finally, Caitong International Asset Management Co. Ltd acquired a new position in Quest Diagnostics during the third quarter worth approximately $33,000. Institutional investors and hedge funds own 88.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on DGX. Truist Financial lifted their price target on Quest Diagnostics from $220.00 to $225.00 and gave the stock a “hold” rating in a research report on Wednesday, April 22nd. Robert W. Baird lifted their price target on Quest Diagnostics from $224.00 to $229.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 22nd. UBS Group increased their target price on shares of Quest Diagnostics from $210.00 to $220.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 22nd. Mizuho increased their target price on shares of Quest Diagnostics from $210.00 to $235.00 and gave the stock an “outperform” rating in a research note on Thursday, February 12th. Finally, Evercore set a $225.00 target price on shares of Quest Diagnostics in a research note on Tuesday, April 21st. Seven equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $216.58.

Quest Diagnostics Trading Down 0.1%

Shares of DGX opened at $203.61 on Friday. The company has a current ratio of 1.18, a quick ratio of 1.08 and a debt-to-equity ratio of 0.67. The firm’s 50-day moving average is $194.89 and its two-hundred day moving average is $191.78. Quest Diagnostics Incorporated has a twelve month low of $164.65 and a twelve month high of $213.50. The firm has a market capitalization of $22.54 billion, a P/E ratio of 22.50, a PEG ratio of 2.43 and a beta of 0.59.

Quest Diagnostics (NYSE:DGX) last issued its earnings results on Tuesday, April 21st. The medical research company reported $2.50 earnings per share for the quarter, topping the consensus estimate of $2.37 by $0.13. Quest Diagnostics had a net margin of 9.07% and a return on equity of 15.60%. The company had revenue of $2.90 billion for the quarter, compared to analyst estimates of $2.83 billion. During the same period in the prior year, the business posted $1.94 earnings per share. The firm’s revenue for the quarter was up 9.2% compared to the same quarter last year. Quest Diagnostics has set its FY 2026 guidance at 10.630-10.830 EPS. On average, research analysts predict that Quest Diagnostics Incorporated will post 10.72 earnings per share for the current fiscal year.

Quest Diagnostics Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, July 22nd. Stockholders of record on Wednesday, July 8th will be paid a dividend of $0.86 per share. This represents a $3.44 annualized dividend and a dividend yield of 1.7%. The ex-dividend date of this dividend is Wednesday, July 8th. Quest Diagnostics’s payout ratio is 38.01%.

Insider Buying and Selling at Quest Diagnostics

In other news, SVP Karthik Kuppusamy sold 8,147 shares of Quest Diagnostics stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $200.00, for a total transaction of $1,629,400.00. Following the completion of the transaction, the senior vice president owned 13,510 shares of the company’s stock, valued at $2,702,000. The trade was a 37.62% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO J. E. Davis sold 10,000 shares of Quest Diagnostics stock in a transaction on Monday, June 1st. The stock was sold at an average price of $194.14, for a total value of $1,941,400.00. Following the transaction, the chief executive officer directly owned 132,423 shares of the company’s stock, valued at $25,708,601.22. This trade represents a 7.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.88% of the company’s stock.

Quest Diagnostics Profile

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.